Avid Bioservices Inc (CDMO)

[biopharm]

Ambit / Peregrine collaboration.... trying to pull a needle from a haystack this has become and darnet, this puzzle will be pieced together sooner or later....

Looks like the Peregrine/Ambit collaboration is going on a year now and wonder how much PS Targeting has been vialed in the doors of Ambit up till now?

For those that were not aware: Peregrine did not give the order to remove this linkedin profile, like it seemed they had done with the 3 profiles that supports a new manufacturing facility in the works

Sr. Clinical Trial Manager
Ambit Biosciences
January 2014 – Present (1 year)

Peregrine Pharmaceuticals
Sr. Clinical Trial Manager
Peregrine Pharmaceuticals
August 2011 – Present (3 years 5 months)Tustin, CA

http://www.linkedin.com/pub/tom-sklenar/29/772/899

---------------------------

Ambit was also at ASH this past weekend and for Leukemia treatment...seems AML will benefit from a little PS Targeting so is there more that Ambit is not saying and playing by Peregrines new rules of restricting as much info as possible and small biotechs such as these must play by those rules or they get F'd. No, not that word......but Fargo'd!

Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)

...
..
Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

http://www.erietvnews.com/story/27551187/ambit-biosciences-and-daiichi-sankyo-inc-announce-two-oral-presentations-and-one-poster-highlighting-quizartinib-to-be-presented-at-the-56th-annual

If it seems confusing, it certainly is! When you have "dozens of collaborations" and getting Bavituximab into the hands of as many as possible, this is one hell of an offense that will score many points in the months to come....and just hours away from seeing more shorts cover, gotta love it!